Ipsen has reported positive topline results from its Phase III BEOND migraine program, with Dysport (abobotulinumtoxinA) meeting the primary endpoint in both episodic and chronic migraine prevention trials.
The company said both the E-BEOND trial in episodic migraine and the C-BEOND trial in chronic migraine demonstrated a statistically significant reduction in monthly migraine days compared with placebo.
The results mark a major milestone for botulinum toxin research in migraine, with E-BEOND becoming the first Phase III trial to show statistically significant efficacy for a botulinum toxin in episodic migraine. Combined with the C-BEOND findings, BEOND is the first Phase III clinical program to demonstrate efficacy of a botulinum toxin in preventing both episodic and chronic migraine.
Dysport was well tolerated across both studies, with safety findings consistent with its established profile in approved indications. Ipsen reported no new or unexpected safety signals.
“These results represent a significant advance in the development of botulinum toxin therapies for migraine,” said Christelle Huguet, EVP and Global Head of R&D. “BEOND is the first Phase III program to demonstrate efficacy of a botulinum toxin in both episodic and chronic migraine. Together, these findings position Dysport as a potential first-in-class treatment for a broad migraine population.”
Migraine affects millions of people worldwide and remains a significant neurological condition with substantial unmet treatment needs. The disorder can severely disrupt daily life, affecting patients’ ability to work, make plans, and maintain social activities.
The potential impact of the findings is particularly significant in episodic migraine, which represents a larger patient population than chronic migraine. In the E-BEOND trial, episodic migraine was defined as up to 14 headache days per month, including at least six migraine days. Chronic migraine, evaluated in the C-BEOND trial, was defined as headaches occurring on 15 or more days per month, including at least eight migraine days.
“These Phase III topline results position Dysport as the first botulinum toxin to demonstrate efficacy for both episodic and chronic migraine prevention, supporting an advance in treatment options for patients,” said Cristina Tassorelli, Principal Investigator for the C-BEOND trial.
